• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Chronic renal dysfunction in cirrhosis: A new frontier in hepatology

    2021-04-01 09:13:16RameshKumarRajeevNayanPriyadarshiUtpalAnand
    World Journal of Gastroenterology 2021年11期

    Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand

    Abstract Chronic kidney disease (CKD) in patients with liver cirrhosis has become a new frontier in hepatology. In recent years, a sharp increase in the diagnosis of CKD has been observed among patients with cirrhosis. The rising prevalence of risk factors, such as diabetes, hypertension and nonalcoholic fatty liver disease, appears to have contributed significantly to the high prevalence of CKD. Moreover, the diagnosis of CKD in cirrhosis is now based on a reduction in the estimated glomerular filtration rate of < 60 mL/min over more than 3 mo. This definition has resulted in a better differentiation of CKD from acute kidney injury (AKI), leading to its greater recognition. It has also been noted that a significant proportion of AKI transforms into CKD in patients with decompensated cirrhosis. CKD in cirrhosis can be structural CKD due to kidney injury or functional CKD secondary to circulatory and neurohormonal imbalances. The available literature on combined cirrhosis-CKD is extremely limited, as most attempts to assess renal dysfunction in cirrhosis have so far concentrated on AKI. Due to problems related to glomerular filtration rate estimation in cirrhosis, the absence of reliable biomarkers of CKD and technical difficulties in performing renal biopsy in advanced cirrhosis, CKD in cirrhosis can present many challenges for clinicians. With combined hepatorenal dysfunctions, fluid mobilization becomes problematic, and there may be difficulties with drug tolerance, hemodialysis and decision-making regarding the need for liver vs simultaneous liver and kidney transplantation. This paper offers a thorough overview of the increasingly known CKD in patients with cirrhosis, with clinical consequences and difficulties occurring in the diagnosis and treatment of such patients.

    Key Words: Acute kidney injury; Cirrhosis; Chronic kidney disease; Renal failure; Hepatorenal syndrome; Renal function

    INTRODUCTION

    Most attempts to assess renal impairment in cirrhosis have so far concentrated on acute kidney injury (AKI), and as a result, detailed knowledge of AKI in cirrhosis is now available[1]. However, there is still scarce evidence on the prevalence, clinical impact and treatment of chronic kidney disease (CKD) in cirrhosis. A sharp rise in the diagnosis of CKD among patients with cirrhosis has been observed in recent years. The prevalence of CKD in hospitalized patients with cirrhosis, which used to be approximately 1% in 2005, has now risen to as high as 46.8% in 2019[2,3]. The growing prevalence of CKD in patients with cirrhosis may represent the convergence of several important epidemiological patterns: the continuing increase in the prevalence of metabolic risk factors such as obesity, hypertension and Medicine degree (DM); the increasing prevalence of nonalcoholic fatty liver disease (NAFLD) as a major contributor to the burden of cirrhosis; and the aging cohort of cirrhosis[4-6]. Moreover, some emerging evidence indicates that the risk of developing de novo CKD remains high for AKI survivors[7]. Liver cirrhosis patients are susceptible to developing AKI due to circulatory abnormalities, neurohormonal changes and the involvement of risk factors such as bacterial infection, gastrointestinal bleeding, medication and paracentesis[1,8]. Depending on the severity, length and frequency, AKI increases the risk of developing incident CKD due to decreases in renal mass and nephron number, vascular insufficiency, and maladaptive repair mechanisms[9]. Therefore, rather than separate entities, AKI and CKD may represent a continuum. The term CKD now encompasses both structural CKD due to structural damage to the kidney and functional CKD due to circulatory and neurohormonal imbalances in cirrhosis. The differentiation between various forms of renal dysfunction in cirrhosis is crucial, as each requires a different treatment plan.

    DEFINITION AND CLASSIFICATION

    The definition of CKD in cirrhosis was originally based on a serum creatinine level of > 1.5 mg/dL until 2011, when an updated definition was introduced by a working group composed of experts from various disciplines[10]. The definition endorsed by kidney disease: Improving global outcomes was largely adopted by this group, and CKD was defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/min for more than 3 mo, measured using the Modi?cation of Diet in Renal Disease-6 (MDRD-6) equation. While the group further agreed that the MDRD-6 equation was not perfect for estimating GFR in patients with cirrhosis, it may still be adopted until better alternatives become available. Currently, the diagnosis of CKD does not require corroborating evidence of kidney damage, such as proteinuria, hematuria, abnormal renal imaging or pathology.

    Kidney Disease: Improving Global Outcomes has classified CKD into structural and functional CKD on the basis of the presence or absence of kidney injury. The old entity, type 2 hepatorenal syndrome (HRS), now referred to as HRS-CKD, is essentially a functional CKD[11]. While functional CKD is considered potentially reversible, since biomarkers of renal tubular damage have been found in patients with HRS, this may not exactly be the case[12-14]. Patients with cirrhosis may have several risk factors for developing structural CKD per se, such as DM, NAFLD, and atherosclerosis[4-6]. In addition, persistent renal vasoconstriction in functional CKD can lead to structural changes, transforming it into structural CKD.

    THE GROWING PREVALENCE OF CHRONIC KIDNEY DISEASE IN CIRRHOSIS

    In recent years, not only has the prevalence of CKD increased significantly in the general population, but an increasing rise in the prevalence of CKD has also been reported in patients with cirrhosis (Table 1)[3,15-17]. The prevalence rates of CKD in cirrhosis, however, vary significantly across studies due to variations in parameters used to describe CKD and differences in the severity of patients with chronic liver disease (CLD).

    In a study by Rustgi et al[18], although the prevalence of CKD among 94431 patients with cirrhosis collected from the insurance claim database was 3.37%, the proportion of patients with decompensated cirrhosis was higher in the combined CLD-CKD group (27.2% vs 11.8%), suggesting that the prevalence of CKD increases with the severity of CLD. In a recent retrospective analysis of a large cohort of patients with cirrhosis (n = 78640) awaiting liver transplantation (LT), while the prevalence of CKD was 7.8% in 2002, it increased to 14.6% in 2017. This is a documented increase in the CKD prevalence rate of 187% in just 15 years. Moreover, among 39719 LT recipients, 6269 (16%) patients met the CKD criteria at the time of last transplant[4]. Another study evaluating the prospectively managed database of the North American Consortium for the End-Stage Liver Disease Study reported a 46.8% prevalence of CKD among 2346 admitted patients with cirrhosis[3]. In an Indian study, the occurrence of CKD was observed in 32.8% of a large prospective cohort (n = 818) of patients with cirrhosis[16]. Functional CKD is considered to be relatively uncommon and accounts for only approximately 3.9% to 15.8% of renal impairments among hospitalized cirrhotic patients; however, new data need to be developed in light of the updated concept of CKD in cirrhosis[2,19].

    DETERMINANTS OF INCREASING CHRONIC KIDNEY DISEASE IN CIRRHOSIS

    Apart from the aging and the high incidence of AKI in cirrhosis, a rising recognition of this condition and a rising trend in the prevalence of DM, hypertension and NAFLD seem to be the key factors behind the increased prevalence of CKD in cirrhosis (Figure 1).

    AKI to CKD transition

    AKI is an independent risk factor for developing CKD in the general population. AKI to CKD transition appears to reflect a continuum. In a meta-analysis of 13 studies, the pooled adjusted hazard ratio for developing CKD among patients with AKI was 8.8 (95% confidence interval: 3.1-25.5)[20]. AKI occurs very frequently in patients with decompensated cirrhosis because of pre-existing circulatory abnormalities, neurohormonal changes and the involvement of risk factors such as DM, bacterial infection, gastrointestinal bleeding, medications and therapeutic paracentesis[1,7,10,11]. Emerging data suggest that in patients with decompensated cirrhosis, a large proportion of AKI progresses to CKD. In a recent study, 25% of patients with decompensated cirrhosis with AKI who survived for at least 3 mo developed CKD, compared with only 1% of those without AKI[7]. Moreover, the odds of developing CKD in patients with decompensated cirrhosis with AKI were 31, suggesting that they are more prone to CKD development than general AKI patients. A higher transition from AKI to CKD was seen when the severity of AKI was higher and when it developed after hospitalization. In another study published in India, 32.8% of 818 patients with cirrhosis developed CKD, approximately 80% of patients with CKD hadat least one episode of AKI, and one-third of patients with AKI had progression to CKD[16]. The mechanisms underlying AKI-CKD progression are still poorly understood. In general, it is believed to be a result of maladaptive repair in the interstitial, vascular and tubular structures of the kidney[9]. However, it is not clear whether the same mechanisms contribute to the development of CKD in cirrhosis. Patients with higher baseline levels of serum creatinine are more likely to develop AKI and less likely to recover from such AKI episodes[21]. Because DM and hypertension patients are more likely to have intrinsic renal disease, such as diabetic nephropathy or hypertensive nephrosclerosis, they are not only at higher risk of developing AKI episodes but also less likely to recover from these episodes due to a lower renal reserve.

    Table 1 Incidence and prevalence of chronic kidney disease in cirrhosis patients

    Increase in the multiple risk factors

    There has been a substantial increase in the multiple shared risk factors for cirrhosis and CKD over the years. NAFLD is independently and significantly associated with an increased incidence and prevalence of CKD[22,23]. In a recent meta-analysis that included nearly 64000 subjects, NAFLD was associated with an approximately 2-fold increased risk of both prevalent and incident CKD[23]. Multiple factors, such as the proinflammatory environment, insulin resistance, oxidative stress, and the activated renin-angiotensin system, may account for the accelerated development and progression of CKD in NAFLD subjects, apart from the common occurrence of DM and hypertension[24]. In addition, NAFLD has been strongly associated with atherosclerosis, as shown by increased intima media thickness or atherosclerotic plaques in the carotid arteries, and atherosclerosis has been associated with glomerulosclerosis, a process that can lead to CKD[25]. In one study, approximately 20%-25% of LT candidates were found to have severe coronary artery disease, suggesting that atherosclerosis in cirrhosis is not uncommon[26]. Over the last 2 decades, the prevalence of NAFLD and NAFLD-related cirrhosis has also increased considerably[27]. In a study, NAFLD accounted for a substantial rise in simultaneous liver and kidney transplantation (SLKT), from 8.2% in 2002 to 22% in 2011[28]. In cirrhosis, DM is highly prevalent, with recorded prevalence rates ranging from 35% to 71%, which is far higher than in the general population[29]. Glomerulopathy, which can progress to CKD, may be associated with certain specific causes of cirrhosis, such as hepatitis B virus (HBV) or hepatitis C virus (HCV). Glomerular involvement in patients with viral hepatitis occurs via an immune pathogenic mechanism. Circulating immune complexes containing viral antigens have been found in the kidney[30].

    Figure 1 Risk factors associated with chronic kidney disease in patients with liver cirrhosis. A rising trend in the prevalence of medicine degree, hypertension and non-alcoholic fatty liver disease seem to be the key factors behind the increased prevalence of chronic kidney disease in cirrhosis. The risk of developing de-novo chronic kidney disease remains high for acute kidney injury survivors. CKD: Chronic kidney disease; HTN: Hypertension; HBV: Hepatis B virus; HCV: Hepatitis C virus; RAAS: Renin-angiotensin-aldosterone system; SNS: Sympathetic nervous system; AVP: Arginine vasopressin; GI: Gastrointestinal; NAFLD: Non-alcoholic fatty liver disease; HRS: Hepatorenal syndrome; AKI: Acute kidney injury.

    CLINICAL IMPLICATIONS OF CHRONIC KIDNEY DISEASE IN CIRRHOSIS

    In several ways, CKD can affect the clinical manifestations, complications, therapeutic decisions, and outcomes of patients with cirrhosis.

    Impact on clinical manifestations

    Anorexia, anemia, ascites, bleeding tendency and encephalopathy can be independently due to both hepatic and renal diseases, so the contributions from individual diseases are often difficult to determine in patients with cirrhosis with CKD. This may create uncertainty about optimal therapeutic choices, such as requirements of renal replacement therapy. In patients with cirrhosis, CKD may contribute to ascites and edema in various ways, such as nephrogenic ascites, chronic fluid overload, hypoproteinemia, and cardiomyopathy[31]. Refractory ascites is almost universal in patients with functional CKD[32,33]. Due to multiple and complex hemostasis abnormalities, patients with concurrent hepatorenal dysfunction may have a higher tendency to bleed. On the other hand, even thrombotic complications are not unusual in such patients[34]. CKD is an independent cardiovascular mortality risk factor, and it can worsen anemia due to cirrhosis[35,36]. Both CKD and cirrhosis can cause immunodepression, leading to an increased risk of infection[37]. Patients with cirrhosis and CKD appear to have an increased risk of developing malignancy[27,38]. In recent years, NAFLD, which is significantly linked to CKD, has also emerged as one of the leading causes of hepatocellular carcinoma (HCC)[27]. Alcohol, HBV infection and HCV infection are other shared risk factors that can be associated with both HCC and CKD. HCC has been found to be associated with a higher prevalence of CKD than any other cancer[39]. After adjustment for many possible confounders, a lower GFR has been shown to be independently associated with a higher risk of incident renal cell and urothelial cancer[40]. CKD has been shown to be associated with increased mortality from liver, kidney, and urothelial cancers[41].

    Impact on complications and outcomes

    CKD in cirrhosis is associated with poor outcomes and an increased frequency of complications[3,7]. Wong et al[3]found that patients with cirrhosis with CKD had higher rates of superimposed AKI (68% vs 21%), need for dialysis (11% vs 2%) and 30-d mortality rates (16% vs 7%) than patients with cirrhosis without CKD. A 10 mL/min decrease in eGFR was found to be associated with a 13% increase in 30-d mortality in patients with cirrhosis. In a study by Bassegoda et al[7], patients with cirrhosis with CKD had a higher frequency of AKI (75% vs 45%), refractory ascites (25% vs 7%), bacterial infections (58% vs 34%) and LT requirement (25% vs 10%) compared with those without CKD[7]. In addition, the involvement of cirrhosis is independently related to a poor outcome in patients with CKD[42]. CKD impacts not only waitlist mortality but also worsens post-LT survival. Cullaro et al[4]reported that the one-year post-LT mortality rate in patients with CKD was 12%, compared with 9% in those without CKD. In addition, posttransplant renal outcomes may also be affected by the presence of CKD[13].

    Impact on health care utilization

    Wong et al[3]found that cirrhosis patients with CKD had higher rates of hospitalization during the preceding 6 mo (70% vs 63%) than those without CKD. Similarly, Bassegoda et al[7]reported a higher 3-mo readmission rate (67% vs 37%) in cirrhosis-CKD patients compared to cirrhosis alone. A recent study analyzed the usage of health care services and the cost burden associated with CKD in patients with CLD (n = 9869) compared to patients with CLD alone (n = 588586) by using real-world insurance claims data. In a propensity-matched cohort analysis, patients with combined CLDCKD were found to have substantially greater annual per-person all-cause health care costs than patients with CLD alone[18].

    DIAGNOSTIC EVALUATION

    The diagnosis of CKD in cirrhosis is based on GFR. Abnormal urine analysis and/or abnormal findings on renal ultrasonography are usually found in advanced CKD and hence are not required for diagnosis. Cirrhosis can be diagnosed in patients with CKD by histopathology or hepatic ultrasound, as well as by clinical manifestations of portal hypertension and/or hepatic decompensation.

    Since CKD diagnosis in cirrhosis requires a decrease in GFR to < 60 mL/min for 12 wk, a reliable and reproducible method is required to estimate GFR. The direct iothalamate clearance test is the gold standard for GFR measurement; however, the cumbersome technique and lack of widespread availability limit its usage in clinical practice[43]. Several indirect methods are available to calculate eGFR in clinical practice.

    Creatinine-based eGFR

    For the assessment of renal function, an eGFR based on the serum creatinine level is commonly used in clinical practice. In patients with cirrhosis, the most commonly used creatinine-based equation is the MDRD. However, serum creatinine levels in patients with cirrhosis may be unreliable due to hepatic dysfunction causing decreased production of creatine, reduced skeletal muscle mass causing decreased creatine-tocreatinine conversion, increased tubular secretion of creatinine, and underestimation of the serum creatinine level by hyperbilirubinemia[44-46]. Therefore, GFR in cirrhosis is typically overestimated by the creatinine-based equation, where a normal serum creatinine level cannot rule out renal dysfunction. In a meta-analysis, the formula based on creatinine was found to overestimate GFR by 18 mL/min[47]. However, despite limitations and until better substitutes become available, the latest creatininebased MDRD equation (MDRD-6) has been recommended by expert panels to be used in patients with cirrhosis[4,44]. The MDRD-6 equation includes 6 variables: Age, sex, race, serum creatinine, serum albumin, and blood urea nitrogen.

    Cystatin-based eGFR

    Cystatin C is a protein produced by all nucleated cells in the body that is exclusively removed by glomerular filtration. Hepatic function, muscle mass, sex, hyperbilirubinemia and tubular secretion do not affect the level of cystatin C. Therefore, cystatin C-based eGFR may be a better alternative to the serum creatinine-based equation for patients with cirrhosis[48-50]. However, the level of cystatin C is affected by hypoalbuminemia, elevated C-reactive protein and leukocytosis, which may limit its role in estimating GFR in cirrhosis[50,51]. Additionally, in patients with cirrhosis, the diagnostic performance of all cystatin C-based GFR equations has been found to be lower than in those without cirrhosis[44]. Combining serum creatinine and cystatin C in an equation appears to predict GFR more accurately than either alone[52]. However, eGFR measurement based on cystatin C has not yet been approved for routine use in patients with cirrhosis.

    Biomarkers of kidney damage

    The role of conventional urinary markers such as albuminuria is very limited in patients with cirrhosis, which may be because of hypoalbuminemia and relatively increased capillary permeability[44]. In addition, a normal proteinuria or urine examination may not exclude parenchymal changes in the kidney. The recent identification of many urinary biomarkers of renal tubular injury, such as urinary neutrophil gelatinase-associated lipocalin (uNGAL), interleukin-18, liver-type fatty acid-binding protein and kidney injury molecule-1, has revolutionized research into organic renal dysfunction[44,53-55]. These biomarkers have, however, been studied primarily in the context of AKI, and their role in the assessment of CKD is not yet clear. The most extensively assessed biomarker in cirrhotic patients has been uNGAL, an inflammatory biomarker produced by damaged renal tubular cells. The uNGAL levels can help distinguish organic from functional AKI; however, cutoff values for such discrimination lack specificity. In addition, the existence of concomitant infections or prolonged renal vasoconstriction in patients with HRS may significantly increase uNGAL levels, thereby limiting its discriminatory function in patients with cirrhosis[14,53]. In general, uNGAL has a positive correlation with the severity of renal dysfunction in patients with CKD, which indicates its prognostic significance for CKD[53]. However, the prognostic value of uNGAL in patients with cirrhosis with CKD is not known.

    The profiles of urinary microRNAs may be an attractive noninvasive tool for future kidney damage assessment[54]. Other biomarkers, such as osteopontin and metalloproteinase-1 tissue inhibitor, are usually elevated in patients with CKD, but their clinical significance has not yet been established[55].

    Role of duplex Doppler ultrasonography

    Renal duplex Doppler ultrasound is a simple, noninvasive and efficient method that can be used in patients with cirrhosis to study intrarenal hemodynamics (Figure 2). It is a test to assess renal vascular resistance as a vasoconstriction marker, and the renal resistive index (RRI) can be used to detect early renal dysfunction in patients with cirrhosis[56]. In general, there is a progressive increase in RRI as cirrhosis patients move from without ascites to with ascites and then to HRS[57]. Since severe renal vasoconstriction is a feature of HRS, duplex ultrasonography can play a potential role in the assessment of functional CKD in patients with cirrhosis. Furthermore, the RRI can predict CKD progression as it correlates with renal histopathological changes such as glomerular sclerosis, interstitial fibrosis, and arteriolosclerosis[58].

    Differentiation between functional and structural CKD

    It is important to determine what proportion of CKD in cirrhosis is functional due to HRS and what proportion is associated with structural renal damage. Such differentiation has important therapeutic and prognostic implications. This would assist the clinician in deciding on the use of diuretics, vasoconstrictor treatment and the recommendation of LT vs SLKT. Structural CKD patients are more likely to be indolent and have higher survival rates than functional CKD patients[32]. However, in the absence of a renal biopsy, it is often difficult to differentiate a functional CKD from a structural CKD. Abnormal urine analysis (proteinuria > 500 mg/d or hematuria > 50/high power field) and/or abnormal findings on renal ultrasonography (reduced cortical thickness, increased cortical echogenicity and scarring) are features of advanced structural CKD (Figure 2). Currently, no accurate biomarkers are available that can diagnose subclinical renal parenchymal injury or differentiate between reversible and permanent renal injury. Importantly, prolonged renal vasoconstriction in patients with functional CKD may lead to irreversible structural changes in the kidney[32,33]. Studies on the outcome of LT in patients with type 2 HRS have found that 50%-60% of patients develop stage 3 CKD during the posttransplant period, even when HRS reverses[13,59]. Therefore, essentially a long-standing functional CKD can be regarded as structural CKD. In the absence of abnormal early imaging features and reliable biomarkers of CKD, renal biopsy remains the only choice to diagnose and further characterize CKD. However, due to coagulopathy, thrombocytopenia, and the presence of large ascites in cirrhosis, as well as scarred kidneys due to CKD, percutaneous renal biopsy may be technically challenging in patients with decompensated cirrhosis.

    Figure 2 Ultrasonographic image of a 65-year-old diabetic patient with liver cirrhosis and chronic kidney disease. A: The liver outline is irregular (white arrows) and there is ascites around it. The right kidney is small and the parenchymal echogenicity is increased with loss of corticomedullary differentiation (asterisk), suggesting chronic kidney disease; B: Doppler sonogram of the same kidney showed reversal of diastolic flow (orange arrow) with absent end-diastolic velocity, indicating very high resistance vessels.

    Pitfalls in the diagnosis of CKD

    A dramatic rise in the diagnosis of CKD in patients with cirrhosis raises some concerns as to whether, in the absence of any corroborating evidence of renal injury, the dependence solely on eGFR leads to overdiagnosis of CKD[60]. An arbitrary single threshold of eGFR < 60 mL/min might have a high propensity to cause overestimation of CKD in elderly subjects. There is a natural steady decrease in GFR with increasing age, and eGFR levels between 50 and 60 mL/min can be insignificant for older individuals, with very little propensity to progress to symptomatic kidney disease[61]. The risks of overdiagnosis of CKD may be significant in patients with cirrhosis since many of them belong to the old age group. In addition, a varying degree of deterioration in GFR may occur in patients with decompensated cirrhosis due to neurohormonal alterations and circulatory dysfunction well before the detection of overt renal disease, which may lead to overdiagnosis of CKD. Therefore, on the basis of a single eGFR threshold and in the absence of any corroborating evidence of kidney damage, caution before labeling CKD in elderly patients with cirrhosis may be needed. Since creatinine-based equations tend to overestimate the GFR, they can underestimate CKD and thus may provide clinicians with false reassurance. Studies need to be performed to determine whether the diagnosis of CKD in patients with decompensated cirrhosis requires a different GFR cutoff.

    MANAGEMENT IMPLICATIONS

    The presence of CKD in patients with cirrhosis presents many challenges to clinicians with regard to medical care. In particular, fluid mobilization to control ascites and edema becomes a real challenge. The use of diuretic therapy has several limitations. As ascites often reaccumulates rapidly, patients require repeated large volume paracentesis. This puts them at risk of multiple complications, such as worsening circulatory dysfunction, infection and bleeding, in addition to causing discomfort to the patients.

    Diuretic therapy

    Diuretic therapy is often not prescribed in patients with functional CKD because of the concern that it may further worsen renal failure by causing intravascular volume loss and may precipitate electrolyte imbalance[33]. In patients with structural CKD, the use of diuretics seems appropriate to manage ascites and edema. However, a varying degree of diuretic resistance is usually present in patients with CKD. This occurs primarily because of decreased renal blood flow, hyperuricemia and organic anion accumulation[62]. The organic anions, uric acid and hypoalbuminemia interfere with the function of loop diuretics. A higher dose of diuretics is therefore required to overcome diuretic resistance in the presence of CKD.

    There is a lack of evidence to guide clinicians as to which single or combination diuretic agent is most appropriate for these patients. Furosemide is primarily eliminated by the kidney, while torsemide has predominant hepatic clearance[63]. Therefore, if kidney dysfunction is a predominant issue, torsemide might be preferred over furosemide, while in the case of severe hepatic dysfunction, furosemide may be preferred over torsemide. A recent meta-analysis found that coadministration of albumin with furosemide had a modest effect on overcoming diuretic resistance in hypoalbuminemic patients[64]. Correction of metabolic acidosis and hyperuricemia, adequate restriction of fluid and salt intake, and avoidance of medications that interfere with peritubular diuretic uptake, such as nonsteroidal anti-inflammatory drugs and beta-lactam antibiotics, may be other measures to enhance the diuretic response[62]. Spironolactone should be better avoided in advanced CKD to prevent hyperkalemia.

    Vaptans

    Vaptan, an antagonist of vasopressin 2 receptor, may be considered in patients with CKD with cirrhosis who are intolerant to or poorly responsive to diuretics. Tolvaptan has been found to be potentially safe with an efficacy rate of 77% for the treatment of refractory ascites in decompensated cirrhosis patients with coexisting type 2 HRS[65]. Tolvaptan significantly increases urine volume in patients with CKD with liver cirrhosis without worsening renal dysfunction[66]. However, its diuretic response gradually diminishes with progression of the CKD stage[67]. Due to the possible risks of hepatocellular damage identified during a clinical trial involving patients with autosomal dominant polycystic kidney disease, the United States Food and Drug Administration issued a warning for tolvaptan use in 2013. However, very high doses of tolvaptan had been used for a long period of time in this study (120 mg/d for 3 years), and no such adverse effects have been reported from the study on patients with cirrhosis where the recommended dose was much lower.

    Vasoconstrictor therapy

    Midodrine is an orally available α1-agonist that serves as a vasoconstrictor and has been found to have an effect on the systemic hemodynamics of cirrhotic patients. However, midodrine trials in patients with cirrhosis have shown contradictory results. There is insufficient evidence about its use in patients with CKD. In patients with type 2 HRS, midodrine has only a slight beneficial effect on systemic hemodynamics, with no effect on renal hemodynamics[68]. Additionally, treatment with terlipressin or noradrenaline along with albumin appears to have a limited role in patients with CKD. While there are several cases of reversal of type 2 HRS, recurrence after withdrawal of therapy is very common. In addition, evidence on the impact of this treatment on the outcomes of patients is controversial. Few studies have assessed the efficacy of terlipressin in a limited number of patients with type 2 HRS, and the findings have been equivocal[69,70]. In a recent study, 46% of treated patients demonstrated reversal of type 2 HRS; however, nearly half of responders experienced relapse[71]. Furthermore, reversal of type 2 HRS before LT does not appear to provide a major benefit over patients who are untreated or who have failed treatment before LT[13]. Therefore, most of the current guidelines do not recommend vasoconstrictor treatment in functional CKD.

    Transjugular intrahepatic portosystemic shunt

    Transjugular intrahepatic portosystemic shunt (TIPS) decreases portal pressure, improves kidney function and relieves ascites. While it is being used increasingly to treat patients with refractory ascites and functional renal failure, there is limited evidence on its use in patients with advanced CKD. In a study on TIPS in 17 patients with cirrhosis with CKD, Lakhoo et al[72]found that ascites control occurred in 83% of patients but at the expense of a high incidence (47%) of new or worsening hepatic encephalopathy (HE). Michl et al[73]reported improvement in renal function and a decrease in the frequency of paracentesis following TIPS in 10 patients with cirrhosis, including three with structural kidney disease. A recent systematic review and metaanalysis found a potential survival benefit of TIPS in patients with HRS but with a high (49%) incidence of HE. In type 2 HRS, the pooled short-term and 1-year survival rates after TIPS were 86% and 64%, respectively. Moreover, 83% of patients with HRS experienced improvement in renal function after TIPS[74]. In summary, TIPS appears to be very effective in patients with functional CKD, and limited data indicate its effectiveness in structural CKD as well. However, TIPS may increase the incidence of HE, so it should be avoided in patients with encephalopathy, cardiopulmonary disease, and significant hepatic dysfunction.

    Cell-free and concentrated ascites reinfusion therapy

    Cell-free and concentrated ascites reinfusion therapy (CART) is an apheresis therapy in which ascitic fluid is filtered to remove unwanted cells, sterilely concentrated, and then intravenously reinfused[75]. It was introduced in Japan as a novel treatment for refractory ascites in patients with cirrhosis. The potential advantages of CART include its ability to maintain nutritional status, control ascites, and improve quality of life. Unlike large volume paracentesis, CART is not associated with the risk of hypoproteinemia, hemodynamic instability, renal dysfunction or fatigue. It has been used for both cirrhotic and malignant ascites; however, its safety and efficacy need to be assessed in CLD-CKD patients with refractory ascites. CART has been found to be equally as effective as large volume paracentesis plus albumin infusion[76]. However, its routine use can be limited by the high cost of the CART apparatus[77].

    Concerns related to medications

    Since the majority of drugs are metabolized and/or excreted by the hepatorenal system, it is a challenging task to prescribe medicines in patients with advanced cirrhosis with renal impairment[78]. There are no evidence-based guidelines for the use of medicines in such patients. Drugs with significant hepatotoxic or nephrotoxic potential or both need to be avoided in such patients. In addition, the dosage of several antibiotics needs to be modified in accordance with GFR. Nonselective β-blockers can increase mortality in patients with advanced cirrhosis with renal dysfunction due to their adverse impact on cardiac compensation[79]. Treatment with hepatitis B nucleos(t)ide analogues can also raise the risk of lactic acidosis if renal dysfunction is present[80].

    Treatment modifications according to the etiology of cirrhosis

    There are no large controlled studies available to direct appropriate antiviral therapy for patients with CKD with HBV cirrhosis. The use of tenofovir disoproxil fumarate has been associated with a mild risk of CKD progression, but a recent meta-analysis has shown that such a decrease in renal function is inappreciable compared with entecavir[81,82]. Nevertheless, entecavir tends to be the most preferred drug for these patients. However, entecavir therapy may not be as effective in patients with lamivudine resistance, so tenofovir alafenamide, an orally bioavailable tenofovir prodrug with a lower risk of renal toxicity, may be considered in such patients. In patients with HCV-cirrhosis and CKD, high sustained virologic response rates with glecaprevir/pibrentasvir combination in all genotypes and with elbasvir/grazoprevir in genotypes 1 and 4 can be achieved. However, these drugs are largely metabolized in the liver and are therefore not safe in advanced cirrhosis[83]. Patients with advanced decompensated cirrhosis and renal dysfunction are a difficult-to-treat category for which there are no guidelines for treatment; therefore, a treatment decision should be made on a case-by-case basis. While a treatment based on sofosbuvir is not recommended for patients with severe renal impairment, it may be used in patients with mild renal impairment[84]. In patients with nonalcoholic steatohepatitis-CKD, statins have been shown to decrease cardiovascular disease mortality, and sodiumglucose cotransporter-2 inhibitors have been found to slow the progression of CKD and minimize all-cause mortality[85]. However, it is important to determine the role of these drugs in nonalcoholic steatohepatitis-cirrhosis patients with CKD.

    Renal replacement therapy

    The shared symptoms between the two diseases and overestimation of eGFR make it difficult for patients with cirrhosis with CKD to determine the ideal time for commencing renal replacement therapy. The hemodynamic alterations of cirrhosis pose a challenge to maintaining hemodynamic stability during dialysis, where a sudden decrease in intravascular volume due to ultrafiltration may cause hypotension. A sharp change in blood osmolarity and electrolyte levels increases the risk of developing HE. In addition, thrombocytopenia, platelet dysfunction, and coagulopathy due to combined CKD-cirrhosis may increase the risk of bleeding complications. In these patients, peritoneal dialysis may be a better choice because it will not only resolve many problems associated with intermittent HD but will also allow ascitic fluid to be regularly evacuated[86,87]. Studies evaluating the survival of cirrhotic patients on peritoneal dialysis have reported a modest survival rate of 8 to 66 mo[88].

    LT vs SLKT

    Increased post-LT mortality is associated with any form of renal dysfunction. However, most studies evaluating the impact of renal function on post-LT survival do not differentiate between CKD and AKI[4,89,90]. Few studies have reported the progression of CKD, including the development of end-stage renal disease and increased post-LT mortality in cirrhotic patients with CKD receiving LT alone[90-92]. In a recent study, the presence of CKD at the time of LT increased the risk of post-LT mortality by 16%[4]. Thus, there has been a drive to perform more SLKT in patients with combined cirrhosis-CKD. However, in patients with cirrhosis, predicting renal recovery post-LT is difficult, and the degree or severity of CKD that warrants SLKT vs LT remains undefined. The 2012 SLKT summit guidelines indicate that SLKT should be considered for cirrhosis-CKD patients with an eGFR of ≤ 40 mL/min measured by the MDRD-6 equation[93]. Once again, however, the use of SLKT is highly variable, and the role of kidney transplantation in nondialysis CKD is controversial. Singh et al[94]recently reported the outcome of LT only in nine CKD-cirrhosis patients who had persistently low eGFR < 40 mL/min for ≥ 12 wk but relatively normal kidney biopsy findings. Post-LT, eGFR increased in all nine patients within a week and remained stable afterwards; one patient progressed to ESRD 9 years post-LT, and another patient expired 7 years after LT. While no definite conclusions can be drawn from this small study, there is an indication that, in the absence of other indicators of renal injury, low eGFR alone below an arbitrary cutoff value does not constitute an absolute requirement for SLKT in patients with liver cirrhosis. Functional CKD is potentially reversible after LT[13,52]. However, prolonged renal ischemia can cause permanent tubular or glomerular damage that may not recover with LT, leading to post-LT CKD progression. Because the assessment of renal function may be difficult in patients with advanced cirrhosis, a renal biopsy should be considered whenever possible for identifying parenchymal changes and to decide between LT and SLKT. In patients with low eGFR and kidney biopsy showing > 30% glomerulosclerosis and/or interstitial fibrosis, SLKT should be considered[93]. Future prediction models to assist in decision-making between SLKT and LT should consider integrating kidney injury markers, including new CKD biomarkers.

    CONCLUSION

    In conclusion, the incidence of CKD in patients with cirrhosis has increased significantly as a result of a rise in risk factors and a change in the diagnostic criteria from a fixed level of serum creatine to a dynamic change in GFR. The available data on this condition are extremely limited. Future studies on this subject are required to explain several contentious issues. Taking into account the problems related to the calculation of GFR in patients with cirrhosis, the main issue to be addressed would be the refining of diagnostic criteria. The other areas that require future research are the identification of reliable biomarkers of chronic kidney damage, the formulation of management strategies based on phenotypic features of CKD in cirrhosis, and the development of prediction models to assist in decision-making between SLKT and LT.

    国产亚洲精品久久久久久毛片| АⅤ资源中文在线天堂| 少妇人妻一区二区三区视频| 90打野战视频偷拍视频| 亚洲成av人片免费观看| 国产高清三级在线| 在线观看免费视频日本深夜| 亚洲精品成人久久久久久| 亚洲国产精品sss在线观看| 国产精品av视频在线免费观看| 18禁国产床啪视频网站| 久久6这里有精品| 一进一出抽搐动态| 免费观看精品视频网站| 久久国产精品影院| 精品人妻1区二区| 哪里可以看免费的av片| 日本一二三区视频观看| 国产精品一区二区免费欧美| 久久国产精品影院| 久久久成人免费电影| 一夜夜www| 久9热在线精品视频| 午夜福利成人在线免费观看| 久久久久国产精品人妻aⅴ院| 伊人久久大香线蕉亚洲五| 天堂动漫精品| 麻豆成人午夜福利视频| 日韩大尺度精品在线看网址| 亚洲精品在线美女| 99精品欧美一区二区三区四区| 69av精品久久久久久| 欧美中文日本在线观看视频| 国产成+人综合+亚洲专区| 中文字幕av成人在线电影| 91麻豆精品激情在线观看国产| 女人十人毛片免费观看3o分钟| xxxwww97欧美| 国产亚洲精品一区二区www| 久久久久久九九精品二区国产| 97超视频在线观看视频| 桃红色精品国产亚洲av| 精品久久久久久久久久免费视频| 亚洲电影在线观看av| 婷婷六月久久综合丁香| 一个人观看的视频www高清免费观看| 午夜免费激情av| 久久久久国内视频| 精品久久久久久久末码| 亚洲av成人av| 有码 亚洲区| 又粗又爽又猛毛片免费看| 熟妇人妻久久中文字幕3abv| 国产精品亚洲一级av第二区| 999久久久精品免费观看国产| 一区二区三区高清视频在线| 国产亚洲精品久久久久久毛片| 不卡一级毛片| 亚洲国产精品999在线| 一级a爱片免费观看的视频| 久久婷婷人人爽人人干人人爱| 黄片小视频在线播放| 亚洲精品国产精品久久久不卡| 日本免费a在线| 一区二区三区免费毛片| 非洲黑人性xxxx精品又粗又长| 色综合欧美亚洲国产小说| 国产色爽女视频免费观看| 99久久精品一区二区三区| 99国产精品一区二区三区| 国产亚洲精品久久久久久毛片| 亚洲成人精品中文字幕电影| 国产一区二区在线观看日韩 | 亚洲男人的天堂狠狠| 国产毛片a区久久久久| 久久精品国产自在天天线| 欧美zozozo另类| 亚洲人成网站在线播| 激情在线观看视频在线高清| 他把我摸到了高潮在线观看| 青草久久国产| 看片在线看免费视频| 国产乱人视频| 叶爱在线成人免费视频播放| 精品日产1卡2卡| 少妇熟女aⅴ在线视频| 一a级毛片在线观看| 男女视频在线观看网站免费| 两个人看的免费小视频| 色哟哟哟哟哟哟| 99在线人妻在线中文字幕| 麻豆成人午夜福利视频| 搡老熟女国产l中国老女人| 精品久久久久久,| 国内毛片毛片毛片毛片毛片| 日韩欧美在线二视频| 精品不卡国产一区二区三区| 亚洲国产欧洲综合997久久,| aaaaa片日本免费| 又黄又粗又硬又大视频| 久久亚洲精品不卡| tocl精华| 亚洲中文日韩欧美视频| 中文字幕人成人乱码亚洲影| 亚洲精华国产精华精| 国产av一区在线观看免费| 在线观看免费视频日本深夜| 免费高清视频大片| 在线观看日韩欧美| 久久久久精品国产欧美久久久| 国产激情偷乱视频一区二区| 一个人看的www免费观看视频| 免费在线观看影片大全网站| av欧美777| 久久精品影院6| а√天堂www在线а√下载| 桃红色精品国产亚洲av| 国产单亲对白刺激| 一级毛片女人18水好多| 老熟妇乱子伦视频在线观看| 两个人的视频大全免费| 香蕉av资源在线| 综合色av麻豆| 国产精华一区二区三区| 在线观看舔阴道视频| a级一级毛片免费在线观看| 免费看光身美女| 亚洲中文字幕日韩| 日韩欧美精品v在线| 国产精品久久久久久精品电影| 亚洲精品国产精品久久久不卡| 性色av乱码一区二区三区2| 久久精品91无色码中文字幕| 国产69精品久久久久777片| 亚洲午夜理论影院| 亚洲片人在线观看| 亚洲国产欧美人成| xxxwww97欧美| 免费av不卡在线播放| 国产精品一及| 在线看三级毛片| 又黄又爽又免费观看的视频| 在线免费观看的www视频| 最近在线观看免费完整版| 麻豆一二三区av精品| 村上凉子中文字幕在线| 99riav亚洲国产免费| av片东京热男人的天堂| 午夜福利成人在线免费观看| 欧美日韩精品网址| 欧美在线黄色| 国产精品爽爽va在线观看网站| 又紧又爽又黄一区二区| 丰满人妻熟妇乱又伦精品不卡| 内地一区二区视频在线| 男女那种视频在线观看| 午夜精品一区二区三区免费看| 天天一区二区日本电影三级| 久久精品人妻少妇| 午夜免费观看网址| 九九热线精品视视频播放| 欧美成狂野欧美在线观看| 亚洲人成网站在线播| 在线观看舔阴道视频| 国产爱豆传媒在线观看| 亚洲激情在线av| 叶爱在线成人免费视频播放| 国产精品美女特级片免费视频播放器| 精品人妻一区二区三区麻豆 | 色综合婷婷激情| 久久精品91无色码中文字幕| 免费看美女性在线毛片视频| 国产成人福利小说| 99久久无色码亚洲精品果冻| 国产精华一区二区三区| 亚洲人与动物交配视频| 国产真实乱freesex| 97超级碰碰碰精品色视频在线观看| 久久久久性生活片| 在线观看免费午夜福利视频| 首页视频小说图片口味搜索| 欧美中文综合在线视频| 亚洲av成人精品一区久久| 天天一区二区日本电影三级| 国产高潮美女av| 18禁国产床啪视频网站| 亚洲五月天丁香| 亚洲久久久久久中文字幕| 国产精品亚洲美女久久久| 成人三级黄色视频| 一二三四社区在线视频社区8| 久久久久精品性色| av在线老鸭窝| 麻豆久久精品国产亚洲av| 日韩不卡一区二区三区视频在线| 亚洲国产最新在线播放| 国产色爽女视频免费观看| 免费观看av网站的网址| 又大又黄又爽视频免费| 精品久久久精品久久久| 国产一区有黄有色的免费视频 | 只有这里有精品99| 国产v大片淫在线免费观看| 成人午夜精彩视频在线观看| av网站免费在线观看视频 | 亚洲国产精品成人久久小说| 观看免费一级毛片| av.在线天堂| av又黄又爽大尺度在线免费看| 最近手机中文字幕大全| 精品久久久噜噜| 一区二区三区高清视频在线| 国产亚洲午夜精品一区二区久久 | 午夜激情欧美在线| 日韩电影二区| 国产免费一级a男人的天堂| 日韩制服骚丝袜av| 国内精品宾馆在线| 乱码一卡2卡4卡精品| 国产精品一区二区在线观看99 | 免费观看无遮挡的男女| 干丝袜人妻中文字幕| 久久久久久久久久成人| 国产精品综合久久久久久久免费| 爱豆传媒免费全集在线观看| 最近手机中文字幕大全| 又黄又爽又刺激的免费视频.| 熟女电影av网| 中文精品一卡2卡3卡4更新| 2021少妇久久久久久久久久久| 真实男女啪啪啪动态图| 亚洲国产高清在线一区二区三| 97超视频在线观看视频| 成人无遮挡网站| 久久久久久久国产电影| 国产精品.久久久| 综合色av麻豆| 欧美潮喷喷水| 97超视频在线观看视频| 亚洲av在线观看美女高潮| 国产极品天堂在线| 国产淫片久久久久久久久| 少妇高潮的动态图| 观看美女的网站| 联通29元200g的流量卡| 免费电影在线观看免费观看| 丝瓜视频免费看黄片| 亚洲精品日韩在线中文字幕| 欧美日韩国产mv在线观看视频 | 国产又色又爽无遮挡免| 一级片'在线观看视频| 蜜桃久久精品国产亚洲av| 亚洲av中文av极速乱| 免费观看的影片在线观看| www.av在线官网国产| 精品一区在线观看国产| 精品一区二区三卡| 黑人高潮一二区| 国产一级毛片在线| 精品酒店卫生间| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 亚洲精品国产成人久久av| 麻豆av噜噜一区二区三区| 色5月婷婷丁香| 日韩精品有码人妻一区| 最近2019中文字幕mv第一页| 伦理电影大哥的女人| 国产男人的电影天堂91| 久久久久精品性色| 国产午夜精品一二区理论片| 国产黄色免费在线视频| 听说在线观看完整版免费高清| 久久草成人影院| 国产精品1区2区在线观看.| 一本—道久久a久久精品蜜桃钙片 精品乱码久久久久久99久播 | 男女下面进入的视频免费午夜| 精品不卡国产一区二区三区| 久久久久久伊人网av| 婷婷色综合www| 成人欧美大片| 91午夜精品亚洲一区二区三区| 国产精品一区二区三区四区久久| 非洲黑人性xxxx精品又粗又长| 欧美变态另类bdsm刘玥| 国产午夜精品久久久久久一区二区三区| 热99在线观看视频| 亚洲精品视频女| 日韩av免费高清视频| 极品教师在线视频| 我的老师免费观看完整版| 夫妻午夜视频| 亚洲精品国产av蜜桃| 大陆偷拍与自拍| 2022亚洲国产成人精品| 国产一区二区亚洲精品在线观看| 爱豆传媒免费全集在线观看| 乱人视频在线观看| 欧美日韩国产mv在线观看视频 | 婷婷色综合大香蕉| av在线播放精品| 国产大屁股一区二区在线视频| 两个人的视频大全免费| 亚洲欧洲日产国产| 日本黄色片子视频| 大香蕉久久网| 国产精品国产三级国产av玫瑰| 久久久久网色| 18+在线观看网站| 亚洲精品成人久久久久久| 一二三四中文在线观看免费高清| 日韩欧美国产在线观看| 国产成人精品福利久久| 日韩大片免费观看网站| 日韩 亚洲 欧美在线| 欧美激情国产日韩精品一区| 日韩伦理黄色片| 好男人视频免费观看在线| 尤物成人国产欧美一区二区三区| 男的添女的下面高潮视频| 国产精品精品国产色婷婷| 久久草成人影院| 色网站视频免费| 国产成人免费观看mmmm| 国产精品熟女久久久久浪| 一级爰片在线观看| 久久久午夜欧美精品| or卡值多少钱| 午夜福利成人在线免费观看| 欧美人与善性xxx| 久久久色成人| 国产91av在线免费观看| 亚洲在久久综合| 国产av不卡久久| 国产在视频线精品| av在线播放精品| 精品久久久久久成人av| 在线天堂最新版资源| 国产综合精华液| 亚洲欧美成人精品一区二区| 综合色av麻豆| 中国美白少妇内射xxxbb| 夫妻午夜视频| 国产又色又爽无遮挡免| 一级二级三级毛片免费看| 国产又色又爽无遮挡免| 美女xxoo啪啪120秒动态图| 免费av观看视频| 精品一区在线观看国产| 国产亚洲精品av在线| 搡老乐熟女国产| 波多野结衣巨乳人妻| 亚洲欧洲日产国产| 欧美高清成人免费视频www| 夫妻午夜视频| 国产又色又爽无遮挡免| 美女xxoo啪啪120秒动态图| 国产精品不卡视频一区二区| 欧美性感艳星| 国产一区二区三区综合在线观看 | 高清日韩中文字幕在线| 99热这里只有是精品50| 一边亲一边摸免费视频| 小蜜桃在线观看免费完整版高清| 青春草亚洲视频在线观看| 亚洲人成网站在线观看播放| 噜噜噜噜噜久久久久久91| 小蜜桃在线观看免费完整版高清| 欧美性猛交╳xxx乱大交人| kizo精华| 搡老妇女老女人老熟妇| 久久久久久久久久久免费av| 18禁裸乳无遮挡免费网站照片| 精品不卡国产一区二区三区| 2021少妇久久久久久久久久久| 精品熟女少妇av免费看| 好男人在线观看高清免费视频| 我的老师免费观看完整版| 国产片特级美女逼逼视频| 永久免费av网站大全| 成年人午夜在线观看视频 | 久久久久九九精品影院| 寂寞人妻少妇视频99o| 国产精品熟女久久久久浪| 麻豆久久精品国产亚洲av| 在线免费十八禁| 欧美日韩一区二区视频在线观看视频在线 | 97人妻精品一区二区三区麻豆| 69人妻影院| 精品久久久噜噜| 免费看a级黄色片| 国产老妇伦熟女老妇高清| 女人久久www免费人成看片| 亚洲美女视频黄频| 自拍偷自拍亚洲精品老妇| 国语对白做爰xxxⅹ性视频网站| 久久鲁丝午夜福利片| 久久精品综合一区二区三区| 男人狂女人下面高潮的视频| 一区二区三区高清视频在线| 男女视频在线观看网站免费| 久久久久九九精品影院| 亚洲人成网站在线播| 国产精品99久久久久久久久| 久久久欧美国产精品| 91aial.com中文字幕在线观看| 亚洲四区av| 国产黄片美女视频| 狂野欧美激情性xxxx在线观看| 狠狠精品人妻久久久久久综合| 国产精品国产三级专区第一集| 免费观看的影片在线观看| 看免费成人av毛片| 国国产精品蜜臀av免费| 国产综合懂色| 国产 一区精品| 国产麻豆成人av免费视频| 国产男女超爽视频在线观看| 亚洲av一区综合| 秋霞伦理黄片| 国产精品国产三级国产av玫瑰| 亚洲精品日韩在线中文字幕| 最近视频中文字幕2019在线8| 联通29元200g的流量卡| 黑人高潮一二区| 极品少妇高潮喷水抽搐| 亚洲av成人精品一二三区| 亚洲av不卡在线观看| 国产午夜精品久久久久久一区二区三区| 亚洲成人久久爱视频| 国产高潮美女av| 日本欧美国产在线视频| 色网站视频免费| 亚洲高清免费不卡视频| 久久久久国产网址| 日本爱情动作片www.在线观看| 国产欧美日韩精品一区二区| 久久久久久久久大av| 免费黄网站久久成人精品| 日本午夜av视频| 在线观看一区二区三区| 少妇人妻精品综合一区二区| 日本午夜av视频| 精品亚洲乱码少妇综合久久| 国产亚洲91精品色在线| 18+在线观看网站| 搡老妇女老女人老熟妇| 九九在线视频观看精品| 亚洲欧美一区二区三区国产| 日本午夜av视频| av黄色大香蕉| 国产黄a三级三级三级人| 日日摸夜夜添夜夜添av毛片| 毛片一级片免费看久久久久| 精品熟女少妇av免费看| 少妇熟女欧美另类| 久久精品久久久久久噜噜老黄| 午夜久久久久精精品| 天堂√8在线中文| 久久亚洲国产成人精品v| 免费观看无遮挡的男女| 国产成人精品久久久久久| 在线免费观看不下载黄p国产| 亚洲熟女精品中文字幕| 蜜桃久久精品国产亚洲av| av国产免费在线观看| 嘟嘟电影网在线观看| 国产黄频视频在线观看| 简卡轻食公司| av.在线天堂| 能在线免费看毛片的网站| 免费av不卡在线播放| 日本免费a在线| 亚洲无线观看免费| 男女啪啪激烈高潮av片| www.色视频.com| 九九爱精品视频在线观看| 国产真实伦视频高清在线观看| 久99久视频精品免费| 人妻夜夜爽99麻豆av| 毛片女人毛片| 99视频精品全部免费 在线| 国语对白做爰xxxⅹ性视频网站| 全区人妻精品视频| 亚洲国产精品成人综合色| 天堂av国产一区二区熟女人妻| 免费电影在线观看免费观看| 尤物成人国产欧美一区二区三区| 亚洲欧洲国产日韩| 女人被狂操c到高潮| 久久99精品国语久久久| 国产乱来视频区| 汤姆久久久久久久影院中文字幕 | 亚洲精品国产av蜜桃| 国产不卡一卡二| 欧美极品一区二区三区四区| av国产免费在线观看| 国产精品蜜桃在线观看| 亚洲精品成人久久久久久| 国产乱来视频区| 神马国产精品三级电影在线观看| 精品一区二区三区视频在线| 免费观看在线日韩| 亚洲国产最新在线播放| 夫妻性生交免费视频一级片| 插阴视频在线观看视频| 国产极品天堂在线| 又爽又黄a免费视频| 国产黄a三级三级三级人| 国产成人freesex在线| 2021少妇久久久久久久久久久| 免费看a级黄色片| 精品久久久久久久久久久久久| 亚洲国产欧美人成| 国产黄片美女视频| 国产麻豆成人av免费视频| 26uuu在线亚洲综合色| 中文字幕久久专区| 国产av国产精品国产| 大话2 男鬼变身卡| 99久国产av精品| 777米奇影视久久| 十八禁网站网址无遮挡 | 2021天堂中文幕一二区在线观| 精品亚洲乱码少妇综合久久| 搡老乐熟女国产| 亚洲成人av在线免费| 久久人人爽人人片av| 国产精品久久久久久精品电影| 久久久久久久久中文| 美女内射精品一级片tv| 亚洲精品视频女| 精品亚洲乱码少妇综合久久| 舔av片在线| 精品国产一区二区三区久久久樱花 | 亚洲欧美精品专区久久| 天堂影院成人在线观看| 嫩草影院精品99| 精品国产露脸久久av麻豆 | 永久免费av网站大全| 女的被弄到高潮叫床怎么办| 九色成人免费人妻av| 黄色配什么色好看| 亚洲欧美中文字幕日韩二区| 亚洲欧洲国产日韩| 国产精品人妻久久久久久| 日韩欧美精品免费久久| 亚洲欧美精品专区久久| 欧美一级a爱片免费观看看| 91在线精品国自产拍蜜月| 亚洲精品aⅴ在线观看| 中文字幕亚洲精品专区| 欧美另类一区| 老司机影院毛片| 三级国产精品片| 亚州av有码| 成人高潮视频无遮挡免费网站| 日韩亚洲欧美综合| 亚洲激情五月婷婷啪啪| 欧美3d第一页| 80岁老熟妇乱子伦牲交| 美女大奶头视频| 亚洲人成网站在线播| 亚洲国产精品专区欧美| 日韩电影二区| 国产综合精华液| 国产免费又黄又爽又色| 深爱激情五月婷婷| 一个人看的www免费观看视频| 日韩亚洲欧美综合| 亚洲乱码一区二区免费版| 伊人久久国产一区二区| 久久久国产一区二区| 久久久久久久久久成人| 国产精品久久视频播放| 日韩欧美 国产精品| 超碰97精品在线观看| 亚洲伊人久久精品综合| av专区在线播放| 免费观看性生交大片5| 亚洲第一区二区三区不卡| a级毛色黄片| 久久久久久伊人网av| 久久久久久久久中文| 色播亚洲综合网| 国产熟女欧美一区二区| 水蜜桃什么品种好| 男女边摸边吃奶| 成人亚洲精品av一区二区| 国产成人精品婷婷| 尾随美女入室| 男女视频在线观看网站免费| 91久久精品电影网| 蜜桃亚洲精品一区二区三区| 亚洲欧洲国产日韩| 中文字幕久久专区| 99九九线精品视频在线观看视频| 日韩,欧美,国产一区二区三区| 精品国产露脸久久av麻豆 | 久久久久精品性色| 日日啪夜夜撸| 免费黄网站久久成人精品| 久久人人爽人人爽人人片va| 中国美白少妇内射xxxbb| 91久久精品国产一区二区成人| 美女脱内裤让男人舔精品视频| 国产视频首页在线观看| 亚洲人成网站在线播| 九色成人免费人妻av| 色综合色国产| 亚洲欧美一区二区三区国产| 亚洲美女视频黄频| 小蜜桃在线观看免费完整版高清| av卡一久久| 神马国产精品三级电影在线观看| 精品亚洲乱码少妇综合久久|